₹-4.90
(Market cap
₹184 Cr
Recently Viewed
Clear AllMarket cap
₹184 Cr
Revenue (TTM)
₹228 Cr
P/E Ratio
14.7
P/B Ratio
2
Div. Yield
0 %
Today’s Range
52 Week Range
Liquidity
Net Profit (TTM)
₹13 Cr
ROE
14.9 %
ROCE
14.7 %
Industry P/E
29.51
EV/EBITDA
7.8
Debt to Equity
0.7
Book Value
₹80.7
EPS
₹11.7
Face value
10
Shares outstanding
11,485,616
CFO
₹133.82 Cr
EBITDA
₹155.03 Cr
Net Profit
₹45.34 Cr
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Parnax Lab
| 23.1 | 20.2 | 38.1 | 69.6 | 28.1 | 46.9 | 17.0 |
|
BSE Healthcare
| 2.7 | 6.8 | 7.9 | 5.7 | 24.7 | 13.8 | 11.1 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|---|
|
Parnax Lab
| -22.9 | 90.8 | 21.1 | 38.0 | 91.7 | 76.6 | -62.3 |
|
BSE Small Cap
| -6.6 | 29.0 | 47.5 | -1.8 | 62.8 | 32.1 | -6.8 |
|
BSE Healthcare
| -3.3 | 43.1 | 37.0 | -12.1 | 20.9 | 61.4 | -3.5 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price (₹) | Market Cap (₹ Cr) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Parnax Lab
|
160.0 | 183.8 | 228.0 | 12.5 | 9.3 | 15.6 | 14.7 | 2.0 |
| 2,822.7 | 35,289.3 | 5,201.6 | 1,014.6 | 22.9 | 25 | 34.8 | 7.7 | |
| 8,213.0 | 20,543.0 | 2,177.5 | 200.9 | 11.3 | 26.5 | 102.3 | 24.7 | |
| 1,709.0 | 13,002.6 | 2,089.5 | 622.0 | 31.3 | 20.4 | 21.2 | 3.9 | |
| 1,322.9 | 18,325.8 | 3,078.2 | 469.4 | 26.4 | 14.9 | 42.4 | 5.1 | |
| 2,043.4 | 32,884.0 | 4,193.0 | 753.8 | 22.7 | 20.8 | 43.6 | 8.2 | |
| 4,710.6 | 21,538.7 | 2,482.3 | 853.6 | 33.7 | 18.9 | 25.2 | 5.4 | |
| 5,216.9 | 8,622.6 | 1,348.5 | 293.5 | 28.1 | 50.7 | 29.4 | 12.4 | |
| 406.7 | 7,958.2 | 1,432.0 | 149.0 | 19.1 | 7.9 | 53 | 3.2 | |
| 1,036.8 | 9,552.3 | 4,725.6 | 528.7 | 14.9 | 20.7 | 18.7 | 3.2 |
No Review & Analysis are available.
Manufacture of allopathic pharmaceutical preparations
Incorporated
1982
Chairman
--
Managing Director
Mihir Shah
Headquarters
Mumbai, Maharashtra
Website
Our rating system has guided millions of investors in the past 20 years.
Annual Reports
Announcements
View AnnouncementsNo News & Announcements are available.
The share price of Parnax Lab Ltd is ₹160.00 (BSE) as of 30-Apr-2026 IST. Parnax Lab Ltd has given a return of 28.13% in the last 3 years.
The P/E ratio of Parnax Lab Ltd is 14.68 times as on 30-Apr-2026, a 50 discount to its peers’ median range of 29.51 times.
The P/B ratio of Parnax Lab Ltd is 1.98 times as on 30-Apr-2026, a 57 discount to its peers’ median range of 4.56 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
10.67
|
1.48
|
|
2024
|
15.48
|
2.08
|
|
2023
|
6.94
|
0.96
|
|
2022
|
15.68
|
2.79
|
|
2021
|
0.00
|
0.51
|
The 52-week high and low of Parnax Lab Ltd are Rs 169.00 and Rs 85.60 as of 30-Apr-2026.
Parnax Lab Ltd has a market capitalisation of ₹ 184 Cr as on 30-Apr-2026. As per SEBI classification, it is a Small Cap company.
Before investing in Parnax Lab Ltd, assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.